Business
New contract in Huntington's disease
New contract in Huntington's disease.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 0234S IXICO plc 28 September 2017 \n\n28th September 2017\n \nIXICO plc\n \n(\"IXICO\" or the \"Company\")\n \nNew contract in Huntington's disease with US-based pharmaceutical company \n \nIXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract with a customer for its technology enabled imaging services. The contract value is US$690k over a two and a half year term.\n \nThis new contract is for a Phase II clinical trial evaluating the safety and tolerability of a novel treatment for patients with Huntington's disease. As part of the study, IXICO will use its TrialTracker™ digital platform and scientific services to provide a battery of advanced MRI imaging techniques and clinical trial endpoints.\n \nGiulio Cerroni, CEO of IXICO, commented\n \n\"We are delighted to announce this contract, building on our successful track record as the partner of choice in Huntington's disease clinical studies. This new contract further demonstrates the value our customers see in IXICO's deep neurological disease expertise combined with our proprietary digital technologies in providing compliant data standardisation, collection and analysis.\"\n \nFor further information please contact: \n\n\n\n\nIXICO plc \nGiulio Cerroni, Chief Executive Officer\nSusan Lowther, Chief Financial Officer\n\n\n \nTel: +44 20 3763 7499\n\n\n\n\n\n\n\n\n\n\n\n\nShore Capital (Nomad and Broker)\nBidhi Bhoma / Edward Mansfield /James Wolfe\n\n\nTel: +44 20 7408 4090\n\n\n\n\n\n\n\n\n\n\n\n\nFTI Consulting Limited (Investor Relations)\nSimon Conway/Mo Noonan\n\n\nTel: +44 20 3727 1000\n\n\n\n\n \nAbout IXICO\n \nIXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug developmen...